514 results on '"Caligiuri M"'
Search Results
2. Il contributo alla cultura dell’intelligence dell’Università Cattolica
3. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
4. E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia
5. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation
6. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
7. 3-T magnetic resonance imaging simultaneous automated multimodal approach improves detection of ambiguous visual hippocampal sclerosis
8. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
9. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia
10. P1244: ROLE OF SELECT T HELPER CELL MONONUCLEAR CELL SUBSETS PROMOTING EPSTEIN-BARR VIRUS-DRIVEN LYMPHOPROLIFERATIVE DISEASE IN THE HU-PBL-SCID MODEL
11. Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia
12. Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B
13. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia
14. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8
15. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
16. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
17. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML
18. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target
19. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia
20. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
21. Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: A MELD study
22. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia
23. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
24. Identification of blood biomarkers for psychosis using convergent functional genomics
25. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
26. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias
27. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA
28. SCFβ-TRCP and phosphorylation dependent ubiquitination of IκBα catalyzed by Ubc3 and Ubc4
29. Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods
30. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications
31. Amplification of MLL perturbs haematopoiesis and cooperates with MLL partial tandem duplication to induce acute myeloid leukaemia: 1
32. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394
33. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study
34. Cytokines and cancer
35. A quantitative study of levodopa-induced dyskinesia in Parkinson's disease
36. Acute Myeloid Leukemia with Deletion 9q is Associated with CEBPA Loss-of-Function Mutations: O374
37. HIF1A Signaling is a Central Pathobiologic Mediator of MDS
38. E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia
39. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation
40. Elderly blood cancer: survey on factors influencing the management of onco-hematological diseases
41. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
42. 70 IDENTIFICATION AND TARGETING HIF-1A PATHWAY IN MDS DEVELOPMENT AND MAINTENANCE
43. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
44. 12 - HIF1A Signaling is a Central Pathobiologic Mediator of MDS
45. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
46. Immunotherapeutic approaches for hematologic malignancies - Section 1: Natural Killer Cell Alloreactivity in mismatched hematopoietic trasplantation
47. Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
48. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
49. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
50. Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.